GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » Cash Conversion Cycle

Therapeutic Solutions International (Therapeutic Solutions International) Cash Conversion Cycle : -2,983.08 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Therapeutic Solutions International's Days Sales Outstanding for the three months ended in Dec. 2023 was 77.94.
Therapeutic Solutions International's Days Inventory for the three months ended in Dec. 2023 was 203.24.
Therapeutic Solutions International's Days Payable for the three months ended in Dec. 2023 was 3264.26.
Therefore, Therapeutic Solutions International's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was -2,983.08.


Therapeutic Solutions International Cash Conversion Cycle Historical Data

The historical data trend for Therapeutic Solutions International's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therapeutic Solutions International Cash Conversion Cycle Chart

Therapeutic Solutions International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39,926.94 -8,942.06 -2,815.61 -1,630.57 -3,613.28

Therapeutic Solutions International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -347.70 -4,077.99 -3,107.77 -4,414.09 -2,983.08

Competitive Comparison of Therapeutic Solutions International's Cash Conversion Cycle

For the Biotechnology subindustry, Therapeutic Solutions International's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Therapeutic Solutions International's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Therapeutic Solutions International's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Therapeutic Solutions International's Cash Conversion Cycle falls into.



Therapeutic Solutions International Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Therapeutic Solutions International's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=81.11+320.61-4015
=-3,613.28

Therapeutic Solutions International's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=77.94+203.24-3264.26
=-2,983.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Therapeutic Solutions International  (OTCPK:TSOI) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Therapeutic Solutions International Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Traded in Other Exchanges
N/A
Address
701 Wild Rose Lane, Elk City, ID, USA, 83525
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
Executives
Thomas Ichim director 211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg officer: CFO 1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon director, officer: Chairman, President, CEO 4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman officer: VP, Training & Education 2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd director, 10 percent owner PO BOX 2145, RANCHO SANTA FE CA 92067

Therapeutic Solutions International (Therapeutic Solutions International) Headlines

From GuruFocus